NEC Baby Formula Lawsuits: Second-Wave Bellwether Trials Set for August 2026

Judge Rebecca R. Pallmeyer has scheduled three new Similac NEC bellwether trials for August 2026, November 2026, and February 2027 in the Northern District of Illinois. The second wave follows a first round that never reached a jury: the court granted summary judgment to Abbott Laboratories in three consecutive cases due to expert testimony exclusions under federal standards. Meanwhile, state court juries have reached substantial verdicts: a $495 million verdict in Missouri in July 2024 and a $60 million verdict in Illinois in March 2024.

More than 750 cases remain pending in the federal MDL. The contrast between federal summary judgments and nine-figure state verdicts highlights how evidentiary requirements shape case outcomes. With the first second-wave trial approaching, trial preparation focuses heavily on product identification and clinical records.

Federal and State Evidentiary Standards

The NEC formula litigation presents contrasting outcomes between court systems. In federal court, Abbott secured summary judgment in early test cases, while in state courts, plaintiffs have obtained substantial jury awards.

The federal dismissals turned on expert testimony. Judge Pallmeyer excluded key plaintiff expert testimony under the federal Daubert standard, which requires scientific testimony to meet specific reliability and methodological criteria. Without admissible general and specific causation testimony on the record, the court granted summary judgment to Abbott.

State courts operate under distinct procedural rules. Missouri and Illinois apply state-specific evidentiary standards, and juries in both jurisdictions evaluated the causation testimony directly. The Missouri jury awarded $495 million after evaluating medical evidence linking cow's-milk-based formula to necrotizing enterocolitis in preterm infants. Illinois produced a $60 million verdict four months earlier. A defense verdict in Missouri state court in October 2024 demonstrated that outcomes remain fact-dependent across individual infant medical histories.

Second-Wave Bellwether Schedule

The second-wave bellwether schedule focuses exclusively on Similac products, naming Abbott Laboratories in all three matters:

• August 2026: First second-wave trial
• November 2026: Second trial
• February 2027: Third trial

The selection of Similac-specific cases narrows the focus of discovery. While the broader MDL includes claims against both Abbott (Similac) and Mead Johnson/Reckitt (Enfamil), these test cases will evaluate Abbott's product warnings and marketing records.

The underlying claim alleges that formula manufacturers failed to warn neonatologists and parents that cow's-milk-based formula increases the risk of necrotizing enterocolitis in premature infants compared to human donor milk.

Critical Medical Records in NEC Litigation

NEC cases require detailed clinical documentation across multiple healthcare facilities:

NICU records form the primary factual record. These charts document feeding modalities (formula versus mother's milk versus donor milk), nutritional volumes, and administration schedules. For infants hospitalized for weeks or months, feeding logs can span hundreds of pages across distinct shifts.

Gestational age records confirm prematurity and low birth weight, establishing the clinical vulnerability window during which the infant received enteral nutrition.

Product identification remains essential. Hospital charts and nursing notes must document the exact formulation administered, such as Similac Special Care or Enfamil Premature. Formulary logs, nutritional orders, and daily flow sheets are necessary to confirm defendant liability.

Surgical and pathology records document disease progression: operative notes detailing bowel resections or ostomy placements, pathology reports analyzing necrotic tissue, and subsequent pediatric gastroenterology records.

Because premature infants are frequently transferred between regional birth hospitals, tertiary Level IV NICUs, and pediatric surgical centers, records are often distributed across multiple health systems. Reverse search uses insurance data to fill in treatment gaps clients don't always remember, surfacing facilities, dates, and clinicians as needed.

Records generally return in 4 days on average, with roughly 30-40% returned same-day on electronic or portal requests. Each file receives an itemized per-case invoice that flows through as a recoverable case disbursement on settlement statements.

Case Preparation Priorities

For firms managing NEC claims ahead of the August 2026 trial date, several steps are essential:

Evidentiary Priorities Ahead of August 2026

The second-wave bellwether schedule will test whether revised expert disclosures and complete clinical records satisfy federal admissibility standards. With 750+ cases pending on the federal docket, the upcoming trials will provide benchmarks for evaluating formula litigation across both federal and state courts.

Securing complete neonatal charts and establishing clear product identification remain the foundational requirements for every active file.

Sources: AboutLawsuits (second wave), AboutLawsuits (Similac trials), Drugwatch (failed bellwether), Drugwatch (summary judgment), AboutLawsuits (defense verdict), Jurimatic ($495M verdict). Case data current as of March 2026.